MolecularMatch and Liquid Biotech USA Partner on Cancer Diagnostics | GenomeWeb

MolecularMatch and Liquid Biotech USA Partner on Cancer Diagnostics

NEW YORK (GenomeWeb) – MolecularMatch and Liquid Biotech USA plan to partner to develop liquid biopsy technology for cancer, the companies said today.

As part of the partnership, Liquid Biotech, which is developing proprietary circulating tumor cell detection technology, will use MolecularMatch's database to correlate genomic test results with treatments. MolecularMatch, which was founded in 2014, has developed software to match the genetic profile of cancer patients' tumors to clinical trials and available drugs.

MoelcularMatch CEO Kevin Coker said in a statement that the partnership would help bridge the gap between liquid biopsy testing and the "resource-consuming matter of tracking innumerable treatments and trial data."

Liquid Biotech Chairman and CEO Phillip Sass added in the statement that the main advantage of his firm's test is in "early, precision detection," and that MolecularMatch's technology would complement its test by matching the results to available treatment and clinical trials, adding speed.

Liquid Biotech spun out of the University of Pennsylvania and raised $2 million last December to further develop its proprietary circulating tumor cell identification and isolation technology.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.


This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Sponsored by
Twist BioScience

This webinar will cover methodologies for genome-wide screening with CRISPR/Cas9 in human pluripotent stem cells (hPSCs).